Incyte signs CMS Medicaid pricing deal for Jakafi, avoids GUARD/GLOBE mandates

INCYTE CORP

Agreement with CMS enables state Medicaid access to Jakafi and Jakafi XR at prices aligned with a group of advanced industrialized nations.
Company expects to be exempt from proposed CMS GUARD and GLOBE pricing models under the agreement.
Incyte states the deal will not affect its 2026 financial guidance or have a material impact on its future financial outlook.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.